Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Explore essential factors to consider when choosing cash back credit cards. Make informed decisions to maximize your rewards.
23,660 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Palantir just beat earnings, yet its stock fell in after-hours trading as traders priced in slower growth and macro h...
Two AI bets with very different risk profiles surfaced as Microsoft and Palantir reported earnings. Microsoft leans o...
In late May 2026, a 62-year-old engineer with $1.4 in retirement assets begins tapping his 401(K) ahead of Social Sec...
A top cybersecurity name rides a durable, AI-driven megatrend, signaling decades of demand as enterprises simplify an...
June volatility is shaking up high-flyers, turning attention to cash-flow winners. One stock stands out as a no-brain...
AI stocks are navigating a choppy market, but marquee names remain firmly in focus for long-term growth. Here’s a tim...
Imagine you could go back to the moment SpaceX opened to the public and put $5,000 into the stock. This guide breaks ...
NVIDIA’s market value has climbed into the multi-trillion-dollar club as AI demand powers surge in revenue and margin...
New December 2025 data underscores a sizable gap in benefits for claiming at 62 versus waiting to 70, changing how in...
Berkshire Hathaway cut a large portion of its Amazon position and deployed capital into The New York Times, a calcula...
In a volatile AI market, SoundHound AI posts a narrower loss for Q4 2025 and lifts 2025 revenue guidance, underscorin...